Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"60S ribosomal protein L23 pseudogene" refers to a processed pseudogene derived from the coding gene for 60S ribosomal protein L23 (RPL23). Pseudogenes are non-functional copies of genes that have lost their protein-coding ability due to mutations or lack of regulatory sequences[1][3][8]. This pseudogene does not code for a functional protein and is not involved in protein synthesis or cellular processes. There are many such pseudogenes in the human genome, especially for ribosomal proteins, reflecting gene duplication and genome evolution[1][8]. They are not considered valid therapeutic targets or relevant to drug discovery efforts. If your intent is to refer to the *functional* protein (RPL23), that is a component of the 60S ribosomal subunit essential for protein synthesis, but the specific entry here (ENSG00000253800) is not the functional protein-coding gene but rather a *pseudogene* copy—hence not a true target for therapeutic intervention[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L23 pseudogene.